Similar companies
Income Statement (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Revenue | 84M | 19.3% |
| Gross Profit | 55M | 29.2% |
| Cost of Revenue | 29M | 3.9% |
| Operating expense | 61M | 0.5% |
| Net Income | 27M | 74.6% |
| EBITDA | 22M | 2.7% |
Balance Sheet (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Total Assets | 982M | 7% |
| Total Liabilities | 96M | 22.5% |
| Total Equity | 886M | 5.6% |
| Shares Outstanding | 29M | 0.2% |
Cash Flow (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Cash from operations | 59M | 1512.1% |
| Cash from investing | -34M | 77.4% |
| Cash from financing | 3.4M | 68.4% |
EPS
Financial Highlights for Krystal Biotech in Q3 '24
Krystal Biotech reported a revenue of 84M, which is a 19.3% change from the previous quarter. An increase in revenue typically indicates growing demand for the company's products or services. This positive change in revenue is a good sign, suggesting that the company's sales are moving in the right direction.
Gross Profit stood at 55M, marking a 29.2% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 29M, a 3.9% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 61M, showing a -0.5% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was 27M, showing a 74.6% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was 22M, showing a -2.7% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
It was a positive quarter for Krystal Biotech with growth in revenue, gross profit, and net income. A decline in EBITDA signals potential operational challenges or increased costs.
